A Phase 1 interventional study of Bulevirtide and Bulevirtide in Hepatic Impairment and Healthy, sponsored by Gilead Sciences. Completed at 6 sites in United States. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-26.
Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goals of this study are to measure the amount of bulevirtide (BLV) that gets into the blood stream and how long it takes to get rid of it, measure the effect of BLV on bile acids, and evaluate the safety and tolerability of multiple doses of BLV in participants with normal and impaired hepatic (liver) function.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
All individuals:
Individuals With Hepatic Impairment:
Have a diagnosis of chronic (> 6 months), stable hepatic impairment (moderate or severe based upon the -Turcotte (CPT) classification system for moderate or severe hepatic impairment [CPT Class B or C, respectively]) with no clinically significant change in hepatic status (as determined by the investigator) within the 2 months (60 days) prior to screening.
Must meet all of the following laboratory parameters at screening:
Matched Control Individuals With Normal Hepatic Function:
Key Exclusion Criteria:
All Individuals:
Have a history of any of the following:
Individuals With Hepatic Impairment:
Matched Control Individuals With Normal Hepatic Function:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with moderate hepatic impairment will receive BLV 2 mg subcutaneous (SC) injection, once daily for 6 days starting on Day 1.
Drug: Bulevirtide
Control group participants with normal hepatic function matched similar to moderate hepatic impairment participants will receive BLV 2 mg SC injection once daily for 6 days starting on Day 1.
Drug: Bulevirtide
Participants with severe hepatic impairment will receive BLV 2 mg SC injection, once daily for 6 days starting on Day 1.
Drug: Bulevirtide
Control group participants with normal hepatic function matched similar to moderate hepatic impairment participants will receive BLV 2 mg SC injection once daily for 6 days starting on Day 1.
Drug: Bulevirtide
Participants with moderate hepatic impairment will receive BLV 10 mg SC injection, once daily for 6 days starting on Day 1.
Drug: Bulevirtide
Control group participants with normal hepatic function matched similar to moderate hepatic impairment participants will receive BLV 10 mg SC injection once daily for 6 days starting on Day 1.
Drug: Bulevirtide
Participants with severe hepatic impairment will receive BLV 10 mg SC injection, once daily for 6 days starting on Day 1.
Drug: Bulevirtide
Control group participants with normal hepatic function matched similar to moderate hepatic impairment participants will receive BLV 10 mg SC injection once daily for 6 days starting on Day 1.
Drug: Bulevirtide
2 mg administered via subcutaneous injections.
Also known as: Hepcludex®, Myrcludex B
10 mg administered via subcutaneous injections.
Also known as: Hepcludex®, Myrcludex B
Pharmacokinetic (PK) Parameter: AUCtau of Bulevirtide (BLV)
AUCtau was defined as the area under the concentration versus time curve (AUC) over the dosing interval at steady state.
Time frame: Day 6: Predose and up to 24 hours postdose
PK Parameter: Cmax,ss of BLV
Cmax,ss was defined as the maximum observed concentration of drug at steady state.
Time frame: Day 6: Predose and up to 24 hours postdose
PK Parameter: AUC0-24h of BLV
AUC0-24h was defined as the partial area under the concentration versus time curve from time zero to time 24 hours.
Time frame: Day 1: Predose and up to 24 hours postdose
PK Parameter: Tmax of BLV
Tmax was defined as the time (observed time point) of Cmax.
Time frame: Days 1 and 6: Predose and up to 24 hours postdose
PK Parameter: Cmax of BLV
Cmax was defined as the maximum observed plasma concentration of drug.
Time frame: Day 1: Predose and up to 24 hours postdose
PK Parameter: t1/2 of BLV
t1/2 was defined as estimate of the terminal elimination half-life of the drug in plasma, calculated by dividing the natural log of 2 by the terminal elimination rate constant (λz).
Time frame: Day 6: Predose and up to 48 hours postdose
PK Parameter: CLss/F of BLV
CLss/F was defined as the apparent clearance at the steady state (CLss) after administration of the drug: CLss/F = Dose/AUCtau, where "Dose" is the dose of the drug per interval.
Time frame: Day 6: Predose and up to 48 hours postdose
PK Parameter: Vss/F of BLV
Vss/F was defined as the apparent steady-state volume of distribution of the drug.
Time frame: Day 6: Predose and up to 48 hours postdose
Pharmacodynamic (PD) Parameter: Ctrough of Total Bile Acids (BA)
Ctrough was defined as the concentration of total BA at the end of the dosing interval.
Time frame: Predose on Days 2, 3, 4, 5, 7, and 8
PD Parameter: Cmax of Total BA
Cmax was defined as the maximum observed concentration of total BA.
Time frame: Days 1 and 6: Predose and up to 24 hours postdose
PD Parameter: AUC0-24h of Total BA
AUC0-24 was defined as the partial area under the concentration versus time curve from time "0" to time "24" hours for total BA.
Time frame: Days 1 and 6: Predose and up to 24 hours postdose
PD Parameter: NetAUC of Total BA
NetAUC was defined as the positive portion of area under the baseline-adjusted biomarker concentration versus time curve over the dosing interval.
Time frame: Days 1 and 6: Predose and up to 24 hours postdose
PD Parameter: Tmax of Total BA
Tmax was defined as the time (observed time point) of Cmax of total BA.
Time frame: Days 1 and 6: Predose and up to 24 hours postdose
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
TEAEs were defined as any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or any AEs leading to premature discontinuation of study drug. If the AE onset date is the same as the date of study drug start date then the AE onset time must be on or after the study drug start time. If the AE onset time is missing when the start dates were the same, the AE were considered treatment emergent. An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment.
Time frame: First dose date up to Day 6 plus 30 days
Percentage of Participants With Laboratory Abnormalities
Treatment-emergent laboratory abnormalities were defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug plus 30 days. If the relevant baseline laboratory value is missing, any abnormality of at least Grade 1 observed within the time frame specified above will be considered treatment emergent. Grading categories are determined by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 1: mild, Grade 2: moderate, Grade 3: severe or medically significant, Grade 4: life-threatening; Grade 5: Death.
Time frame: First dose date up to Day 6 plus 30 days
Participants were enrolled at study sites in the United States.
| Milestone | Group A: Bulevirtide (BLV) 2 mg, Moderate Hepatic Impairment | Group A: BLV 2 mg, Matched Control | Group B: BLV 2 mg, Severe Hepatic Impairment | Group B: BLV 2 mg, Matched Control | Group C: BLV 10 mg, Moderate Hepatic Impairment | Group C: BLV 10 mg, Matched Control | Group D: BLV 10 mg, Severe Hepatic Impairment | Group D: BLV 10 mg, Matched Control |
|---|---|---|---|---|---|---|---|---|
| Started | 11 | 11 | 8 | 8 | 10 | 10 | 8 | 8 |
| Completed | 10 | 10 | 8 | 8 | 10 | 10 | 8 | 8 |
| Not completed | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
AUCtau was defined as the area under the concentration versus time curve (AUC) over the dosing interval at steady state.
| h*ng/mL | Group A: BLV 2 mg, Moderate Hepatic Impairment | Group A: BLV 2 mg, Matched Control | Group B: BLV 2 mg, Severe Hepatic Impairment | Group B: BLV 2 mg, Matched Control | Group C: BLV 10 mg, Moderate Hepatic Impairment | Group C: BLV 10 mg, Matched Control | Group D: BLV 10 mg, Severe Hepatic Impairment | Group D: BLV 10 mg, Matched Control |
|---|---|---|---|---|---|---|---|---|
| Pharmacokinetic (PK) Parameter: AUCtau of Bulevirtide (BLV) | 152 ± 110 | 150 ± 66.9 | 215 ± 71.7 | 113 ± 45.8 | 1270 ± 776 | 1560 ± 347 | 1520 ± 459 | 1600 ± 502 |
Cmax,ss was defined as the maximum observed concentration of drug at steady state.
| ng/mL | Group A: BLV 2 mg, Moderate Hepatic Impairment | Group A: BLV 2 mg, Matched Control | Group B: BLV 2 mg, Severe Hepatic Impairment | Group B: BLV 2 mg, Matched Control | Group C: BLV 10 mg, Moderate Hepatic Impairment | Group C: BLV 10 mg, Matched Control | Group D: BLV 10 mg, Severe Hepatic Impairment | Group D: BLV 10 mg, Matched Control |
|---|---|---|---|---|---|---|---|---|
| PK Parameter: Cmax,ss of BLV | 29.5 ± 23.8 | 22.7 ± 14.7 | 61.4 ± 27.6 | 15.2 ± 6.64 | 175 ± 113 | 261 ± 64.1 | 293 ± 96.8 | 263 ± 101 |
AUC0-24h was defined as the partial area under the concentration versus time curve from time zero to time 24 hours.
| h*ng/mL | Group A: BLV 2 mg, Moderate Hepatic Impairment | Group A: BLV 2 mg, Matched Control | Group B: BLV 2 mg, Severe Hepatic Impairment | Group B: BLV 2 mg, Matched Control | Group C: BLV 10 mg, Moderate Hepatic Impairment | Group C: BLV 10 mg, Matched Control | Group D: BLV 10 mg, Severe Hepatic Impairment | Group D: BLV 10 mg, Matched Control |
|---|---|---|---|---|---|---|---|---|
| PK Parameter: AUC0-24h of BLV | 82.9 ± 55.2 | 54.0 ± 12.8 | 174 ± 77.9 | 51.2 ± 8.90 | 672 ± 434 | 850 ± 337 | 1220 ± 350 | 750 ± 376 |
Tmax was defined as the time (observed time point) of Cmax.
| hours | Group A: BLV 2 mg, Moderate Hepatic Impairment | Group A: BLV 2 mg, Matched Control | Group B: BLV 2 mg, Severe Hepatic Impairment | Group B: BLV 2 mg, Matched Control | Group C: BLV 10 mg, Moderate Hepatic Impairment | Group C: BLV 10 mg, Matched Control | Group D: BLV 10 mg, Severe Hepatic Impairment | Group D: BLV 10 mg, Matched Control |
|---|---|---|---|---|---|---|---|---|
| Day 1 | 1.50 (0.500 to 3.00) | 1.48 (1.00 to 2.00) | 1.00 (0.983 to 1.50) | 1.50 (1.00 to 2.03) | 4.00 (1.00 to 9.00) | 5.00 (2.00 to 9.00) | 3.00 (1.50 to 4.00) | 5.00 (1.50 to 9.00) |
| Day 6 | 1.38 (0.500 to 1.60) | 1.51 (1.03 to 3.00) | 1.02 (1.00 to 1.50) | 1.75 (1.00 to 3.00) | 3.00 (3.00 to 6.00) | 3.00 (2.00 to 4.00) | 2.50 (2.00 to 3.00) | 3.00 (2.97 to 4.00) |
Cmax was defined as the maximum observed plasma concentration of drug.
| ng/mL | Group A: BLV 2 mg, Moderate Hepatic Impairment | Group A: BLV 2 mg, Matched Control | Group B: BLV 2 mg, Severe Hepatic Impairment | Group B: BLV 2 mg, Matched Control | Group C: BLV 10 mg, Moderate Hepatic Impairment | Group C: BLV 10 mg, Matched Control | Group D: BLV 10 mg, Severe Hepatic Impairment | Group D: BLV 10 mg, Matched Control |
|---|---|---|---|---|---|---|---|---|
| PK Parameter: Cmax of BLV | 23.7 ± 15.2 | 12.6 ± 4.28 | 57.7 ± 24.2 | 12.4 ± 3.84 | 99.2 ± 94.3 | 127 ± 65.6 | 230 ± 85.4 | 103 ± 69.6 |
t1/2 was defined as estimate of the terminal elimination half-life of the drug in plasma, calculated by dividing the natural log of 2 by the terminal elimination rate constant (λz).
| hours | Group A: BLV 2 mg, Moderate Hepatic Impairment | Group A: BLV 2 mg, Matched Control | Group B: BLV 2 mg, Severe Hepatic Impairment | Group B: BLV 2 mg, Matched Control | Group C: BLV 10 mg, Moderate Hepatic Impairment | Group C: BLV 10 mg, Matched Control | Group D: BLV 10 mg, Severe Hepatic Impairment | Group D: BLV 10 mg, Matched Control |
|---|---|---|---|---|---|---|---|---|
| PK Parameter: t1/2 of BLV | 3.34 ± 1.31 | 2.86 ± 0.686 | 2.31 ± 0.791 | 5.05 ± 2.39 | 3.49 ± 1.15 | 2.80 ± 0.795 | 2.78 ± 0.750 | 3.33 ± 0.975 |
CLss/F was defined as the apparent clearance at the steady state (CLss) after administration of the drug: CLss/F = Dose/AUCtau, where "Dose" is the dose of the drug per interval.
| L/h | Group A: BLV 2 mg, Moderate Hepatic Impairment | Group A: BLV 2 mg, Matched Control | Group B: BLV 2 mg, Severe Hepatic Impairment | Group B: BLV 2 mg, Matched Control | Group C: BLV 10 mg, Moderate Hepatic Impairment | Group C: BLV 10 mg, Matched Control | Group D: BLV 10 mg, Severe Hepatic Impairment | Group D: BLV 10 mg, Matched Control |
|---|---|---|---|---|---|---|---|---|
| PK Parameter: CLss/F of BLV | 22.1 ± 13.9 | 15.8 ± 7.21 | 9.97 ± 2.46 | 19.8 ± 7.20 | 9.63 ± 3.88 | 6.70 ± 1.62 | 7.06 ± 1.98 | 6.76 ± 2.10 |
Vss/F was defined as the apparent steady-state volume of distribution of the drug.
| liters | Group A: BLV 2 mg, Moderate Hepatic Impairment | Group A: BLV 2 mg, Matched Control | Group B: BLV 2 mg, Severe Hepatic Impairment | Group B: BLV 2 mg, Matched Control | Group C: BLV 10 mg, Moderate Hepatic Impairment | Group C: BLV 10 mg, Matched Control | Group D: BLV 10 mg, Severe Hepatic Impairment | Group D: BLV 10 mg, Matched Control |
|---|---|---|---|---|---|---|---|---|
| PK Parameter: Vss/F of BLV | 119 ± 100 | 70.7 ± 46.3 | 34.4 ± 16.1 | 148 ± 78.8 | 52.6 ± 33.5 | 27.8 ± 13.9 | 28.4 ± 11.9 | 34.5 ± 19.4 |
Ctrough was defined as the concentration of total BA at the end of the dosing interval.
| uM | Group A: BLV 2 mg, Moderate Hepatic Impairment | Group A: BLV 2 mg, Matched Control | Group B: BLV 2 mg, Severe Hepatic Impairment | Group B: BLV 2 mg, Matched Control | Group C: BLV 10 mg, Moderate Hepatic Impairment | Group C: BLV 10 mg, Matched Control | Group D: BLV 10 mg, Severe Hepatic Impairment | Group D: BLV 10 mg, Matched Control |
|---|---|---|---|---|---|---|---|---|
| Day 2 | 26.5 ± 27.1 | 4.68 ± 3.06 | 223 ± 131 | 5.18 ± 4.79 | 50.6 ± 55.1 | 25.7 ± 19.6 | 158 ± 60.5 | 31.0 ± 25.5 |
| Day 3 | 46.3 ± 49.7 | 7.96 ± 7.00 | 213 ± 132 | 6.60 ± 2.74 | 67.2 ± 70.9 | 22.6 ± 9.53 | 180 ± 69.4 | 29.5 ± 25.1 |
| Day 4 | 41.9 ± 50.5 | 6.86 ± 3.58 | 192 ± 121 | 6.03 ± 5.32 | 57.3 ± 46.0 | 23.3 ± 14.8 | 157 ± 87.1 | 16.1 ± 8.68 |
| Day 5 | 30.5 ± 23.3 | 7.65 ± 3.85 | 201 ± 119 | 7.96 ± 6.01 | 50.6 ± 26.2 | 25.1 ± 12.2 | 176 ± 96.1 | 23.7 ± 13.9 |
| Day 7 | 38.2 ± 37.3 | 10.2 ± 5.55 | 170 ± 91.3 | 8.44 ± 7.68 | 80.7 ± 65.9 | 21.8 ± 13.7 | 222 ± 97.0 | 25.9 ± 16.0 |
| Day 8 | 33.4 ± 37.4 | 6.76 ± 5.62 | 151 ± 82.0 | 5.69 ± 3.73 | 37.1 ± 53.1 | 7.29 ± 3.73 | 129 ± 78.9 | 11.0 ± 9.21 |
Cmax was defined as the maximum observed concentration of total BA.
| uM | Group A: BLV 2 mg, Moderate Hepatic Impairment | Group A: BLV 2 mg, Matched Control | Group B: BLV 2 mg, Severe Hepatic Impairment | Group B: BLV 2 mg, Matched Control | Group C: BLV 10 mg, Moderate Hepatic Impairment | Group C: BLV 10 mg, Matched Control | Group D: BLV 10 mg, Severe Hepatic Impairment | Group D: BLV 10 mg, Matched Control |
|---|---|---|---|---|---|---|---|---|
| Day 1 | 46.6 ± 61.4 | 15.6 ± 15.4 | 317 ± 156 | 13.1 ± 4.30 | 176 ± 99.7 | 145 ± 44.5 | 305 ± 40.9 | 150 ± 72.0 |
| Day 6 | 124 ± 117 | 85.5 ± 42.2 | 318 ± 97.9 | 62.9 ± 44.6 | 343 ± 134 | 180 ± 35.8 | 370 ± 51.7 | 221 ± 78.9 |
AUC0-24 was defined as the partial area under the concentration versus time curve from time "0" to time "24" hours for total BA.
| uM*h | Group A: BLV 2 mg, Moderate Hepatic Impairment | Group A: BLV 2 mg, Matched Control | Group B: BLV 2 mg, Severe Hepatic Impairment | Group B: BLV 2 mg, Matched Control | Group C: BLV 10 mg, Moderate Hepatic Impairment | Group C: BLV 10 mg, Matched Control | Group D: BLV 10 mg, Severe Hepatic Impairment | Group D: BLV 10 mg, Matched Control |
|---|---|---|---|---|---|---|---|---|
| Day 1 | 766 ± 1010 | 195 ± 174 | 5870 ± 2930 | 168 ± 69.5 | 2270 ± 1440 | 1690 ± 348 | 5130 ± 918 | 1760 ± 748 |
| Day 6 | 1840 ± 1790 | 1000 ± 391 | 5680 ± 2010 | 720 ± 472 | 4640 ± 2010 | 2330 ± 527 | 6840 ± 1250 | 2920 ± 1150 |
NetAUC was defined as the positive portion of area under the baseline-adjusted biomarker concentration versus time curve over the dosing interval.
| uM*h | Group A: BLV 2 mg, Moderate Hepatic Impairment | Group A: BLV 2 mg, Matched Control | Group B: BLV 2 mg, Severe Hepatic Impairment | Group B: BLV 2 mg, Matched Control | Group C: BLV 10 mg, Moderate Hepatic Impairment | Group C: BLV 10 mg, Matched Control | Group D: BLV 10 mg, Severe Hepatic Impairment | Group D: BLV 10 mg, Matched Control |
|---|---|---|---|---|---|---|---|---|
| Day 1 | 259 ± 345 | 133 ± 154 | 1790 ± 1430 | 113 ± 66.9 | 1880 ± 1020 | 1630 ± 334 | 2380 ± 781 | 1690 ± 731 |
| Day 6 | 768 ± 773 | 925 ± 392 | 1880 ± 1120 | 657 ± 467 | 4210 ± 1410 | 2270 ± 542 | 4030 ± 1220 | 2850 ± 1140 |
Tmax was defined as the time (observed time point) of Cmax of total BA.
| hours | Group A: BLV 2 mg, Moderate Hepatic Impairment | Group A: BLV 2 mg, Matched Control | Group B: BLV 2 mg, Severe Hepatic Impairment | Group B: BLV 2 mg, Matched Control | Group C: BLV 10 mg, Moderate Hepatic Impairment | Group C: BLV 10 mg, Matched Control | Group D: BLV 10 mg, Severe Hepatic Impairment | Group D: BLV 10 mg, Matched Control |
|---|---|---|---|---|---|---|---|---|
| Day 1 | 9.08 (-0.500 to 12.0) | 9.00 (6.00 to 23.5) | 7.50 (4.00 to 12.0) | 12.0 (6.00 to 24.7) | 12.0 (6.00 to 12.0) | 10.5 (6.00 to 12.1) | 12.0 (6.00 to 12.0) | 10.6 (9.00 to 12.0) |
| Day 6 | 6.02 (1.50 to 12.0) | 9.00 (6.00 to 12.0) | 7.50 (6.00 to 12.0) | 10.5 (4.00 to 12.1) | 12.0 (6.00 to 12.0) | 9.00 (3.00 to 12.0) | 12.0 (6.00 to 12.1) | 10.5 (6.00 to 12.0) |
TEAEs were defined as any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug and/or any AEs leading to premature discontinuation of study drug. If the AE onset date is the same as the date of study drug start date then the AE onset time must be on or after the study drug start time. If the AE onset time is missing when the start dates were the same, the AE were considered treatment emergent. An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment.
| percentage of participants | Group A: BLV 2 mg, Moderate Hepatic Impairment | Group A: BLV 2 mg, Matched Control | Group B: BLV 2 mg, Severe Hepatic Impairment | Group B: BLV 2 mg, Matched Control | Group C: BLV 10 mg, Moderate Hepatic Impairment | Group C: BLV 10 mg, Matched Control | Group D: BLV 10 mg, Severe Hepatic Impairment | Group D: BLV 10 mg, Matched Control |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | 27.3 | 9.1 | 25.0 | 12.5 | 20.0 | 20.0 | 25.0 | 25.0 |
Treatment-emergent laboratory abnormalities were defined as values that increase at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug plus 30 days. If the relevant baseline laboratory value is missing, any abnormality of at least Grade 1 observed within the time frame specified above will be considered treatment emergent. Grading categories are determined by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Grade 1: mild, Grade 2: moderate, Grade 3: severe or medically significant, Grade 4: life-threatening; Grade 5: Death.
| percentage of participants | Group A: BLV 2 mg, Moderate Hepatic Impairment | Group A: BLV 2 mg, Matched Control | Group B: BLV 2 mg, Severe Hepatic Impairment | Group B: BLV 2 mg, Matched Control | Group C: BLV 10 mg, Moderate Hepatic Impairment | Group C: BLV 10 mg, Matched Control | Group D: BLV 10 mg, Severe Hepatic Impairment | Group D: BLV 10 mg, Matched Control |
|---|---|---|---|---|---|---|---|---|
| Any Grade 1 or Higher | 63.6 | 63.6 | 100.0 | 62.5 | 90.0 | 90.0 | 75.0 | 50.0 |
| Grade 3 or 4 | 0.0 | 0.0 | 0.0 | 0.0 | 10.0 | 0.0 | 25.0 | 0.0 |
Collected over Up to Day 6 plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group A: BLV 2 mg, Moderate Hepatic Impairment | 0/11 (0%) | 0/11 (0%) | 3/11 (27.3%) |
| Group A: BLV 2 mg, Matched Control | 0/11 (0%) | 0/11 (0%) | 1/11 (9.1%) |
| Group B: BLV 2 mg, Severe Hepatic Impairment | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Group B: BLV 2 mg, Matched Control | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Group C: BLV 10 mg, Moderate Hepatic Impairment | 0/10 (0%) | 0/10 (0%) | 2/10 (20%) |
| Group C: BLV 10 mg, Matched Control | 0/10 (0%) | 0/10 (0%) | 2/10 (20%) |
| Group D: BLV 10 mg, Severe Hepatic Impairment | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Group D: BLV 10 mg, Matched Control | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Event | Group A: BLV 2 mg, Moderate Hepatic Impairment | Group A: BLV 2 mg, Matched Control | Group B: BLV 2 mg, Severe Hepatic Impairment | Group B: BLV 2 mg, Matched Control | Group C: BLV 10 mg, Moderate Hepatic Impairment | Group C: BLV 10 mg, Matched Control | Group D: BLV 10 mg, Severe Hepatic Impairment | Group D: BLV 10 mg, Matched Control |
|---|---|---|---|---|---|---|---|---|
| Alanine aminotransferase increasedInvestigations | 0/11 | 0/11 | 0/8 | 0/8 | 0/10 | 2/10 | 0/8 | 0/8 |
| Abdominal painGastrointestinal disorders | 0/11 | 0/11 | 1/8 | 0/8 | 0/10 | 0/10 | 0/8 | 0/8 |
| Peripheral swellingGeneral disorders | 0/11 | 0/11 | 0/8 | 0/8 | 0/10 | 0/10 | 1/8 | 0/8 |
| PyrexiaGeneral disorders | 0/11 | 0/11 | 0/8 | 1/8 | 0/10 | 0/10 | 0/8 | 0/8 |
| Blood creatinine increasedInvestigations | 0/11 | 0/11 | 0/8 | 0/8 | 0/10 | 0/10 | 1/8 | 0/8 |
| Electrocardiogram QT prolongedInvestigations | 0/11 | 0/11 | 1/8 | 0/8 | 0/10 | 0/10 | 0/8 | 0/8 |
| Transaminases increasedInvestigations | 0/11 | 0/11 | 0/8 | 0/8 | 0/10 | 0/10 | 0/8 | 1/8 |
| DizzinessNervous system disorders | 0/11 | 0/11 | 1/8 | 0/8 | 0/10 | 0/10 | 1/8 | 0/8 |
| HeadacheNervous system disorders | 1/11 | 0/11 | 0/8 | 0/8 | 0/10 | 0/10 | 0/8 | 1/8 |
| ConstipationGastrointestinal disorders | 0/11 | 0/11 | 0/8 | 0/8 | 1/10 | 0/10 | 0/8 | 0/8 |
The Safety Analysis Set included all participants who took at least 1 dose of study drug BLV.
| Age, Categorical(Participants) | Group A: BLV 2 mg, Moderate Hepatic Impairment | Group A: BLV 2 mg, Matched Control | Group B: BLV 2 mg, Severe Hepatic Impairment | Group B: BLV 2 mg, Matched Control | Group C: BLV 10 mg, Moderate Hepatic Impairment | Group C: BLV 10 mg, Matched Control | Group D: BLV 10 mg, Severe Hepatic Impairment | Group D: BLV 10 mg, Matched Control | Total |
|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 10 | 7 | 7 | 7 | 8 | 8 | 7 | 61 |
| >=65 years | 4 | 1 | 1 | 1 | 3 | 2 | 0 | 1 | 13 |
| Age, Continuous(years) | Group A: BLV 2 mg, Moderate Hepatic Impairment | Group A: BLV 2 mg, Matched Control | Group B: BLV 2 mg, Severe Hepatic Impairment | Group B: BLV 2 mg, Matched Control | Group C: BLV 10 mg, Moderate Hepatic Impairment | Group C: BLV 10 mg, Matched Control | Group D: BLV 10 mg, Severe Hepatic Impairment | Group D: BLV 10 mg, Matched Control | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 59 ± 10.5 | 56 ± 7.4 | 47 ± 12.5 | 46 ± 12.7 | 61 ± 7.4 | 59 ± 6.0 | 52 ± 7.7 | 53 ± 8.6 | 55 ± 10.2 |
| Sex: Female, Male(Participants) | Group A: BLV 2 mg, Moderate Hepatic Impairment | Group A: BLV 2 mg, Matched Control | Group B: BLV 2 mg, Severe Hepatic Impairment | Group B: BLV 2 mg, Matched Control | Group C: BLV 10 mg, Moderate Hepatic Impairment | Group C: BLV 10 mg, Matched Control | Group D: BLV 10 mg, Severe Hepatic Impairment | Group D: BLV 10 mg, Matched Control | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 3 | 4 | 4 | 3 | 3 | 3 | 3 | 26 |
| Male | 8 | 8 | 4 | 4 | 7 | 7 | 5 | 5 | 48 |
| Ethnicity (NIH/OMB)(Participants) | Group A: BLV 2 mg, Moderate Hepatic Impairment | Group A: BLV 2 mg, Matched Control | Group B: BLV 2 mg, Severe Hepatic Impairment | Group B: BLV 2 mg, Matched Control | Group C: BLV 10 mg, Moderate Hepatic Impairment | Group C: BLV 10 mg, Matched Control | Group D: BLV 10 mg, Severe Hepatic Impairment | Group D: BLV 10 mg, Matched Control | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 7 | 7 | 5 | 7 | 8 | 6 | 6 | 6 | 52 |
| Not Hispanic or Latino | 4 | 4 | 3 | 1 | 2 | 4 | 2 | 2 | 22 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Group A: BLV 2 mg, Moderate Hepatic Impairment | Group A: BLV 2 mg, Matched Control | Group B: BLV 2 mg, Severe Hepatic Impairment | Group B: BLV 2 mg, Matched Control | Group C: BLV 10 mg, Moderate Hepatic Impairment | Group C: BLV 10 mg, Matched Control | Group D: BLV 10 mg, Severe Hepatic Impairment | Group D: BLV 10 mg, Matched Control | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 0 | 0 | 0 | 1 | 0 | 2 | 6 |
| White | 10 | 9 | 8 | 8 | 10 | 9 | 8 | 6 | 68 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Group A: BLV 2 mg, Moderate Hepatic Impairment | Group A: BLV 2 mg, Matched Control | Group B: BLV 2 mg, Severe Hepatic Impairment | Group B: BLV 2 mg, Matched Control | Group C: BLV 10 mg, Moderate Hepatic Impairment | Group C: BLV 10 mg, Matched Control | Group D: BLV 10 mg, Severe Hepatic Impairment | Group D: BLV 10 mg, Matched Control | Total |
|---|---|---|---|---|---|---|---|---|---|
| United States | 11 | 11 | 8 | 8 | 10 | 10 | 8 | 8 | 74 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2023 to primary completion in Jan 2025, 21 months.
Results were first posted in Jan 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bulevirtide